Male‐Biased Gut Microbiome and Metabolites Aggravate Colorectal Cancer Development
Ling Wang, Yi‐Xuan Tu, Lu Chen, Yuan Zhang, Xier Pan, Shu‐Qiao Yang, Shuai‐Jie Zhang, Shenghui Li, Ke‐Chun Yu, Shuo Song, Hongli Xu, Zhucheng Yin, Junqiu Yue, Qian‐Lin Ni, Tang Tang, Jiu‐liang Zhang, Min Guo, Shuai Zhang, Fan Yao, Xinjun Liang, Zhen‐Xia Chen
Abstract
Abstract Men demonstrate higher incidence and mortality rates of colorectal cancer (CRC) than women. This study aims to explain the potential causes of such sexual dimorphism in CRC from the perspective of sex‐biased gut microbiota and metabolites. The results show that sexual dimorphism in colorectal tumorigenesis is observed in both Apc Min/ + mice and azoxymethane (AOM)/dextran sulfate sodium (DSS)‐treated mice with male mice have significantly larger and more tumors, accompanied by more impaired gut barrier function. Moreover, pseudo‐germ mice receiving fecal samples from male mice or patients show more severe intestinal barrier damage and higher level of inflammation. A significant change in gut microbiota composition is found with increased pathogenic bacteria Akkermansia muciniphila and deplets probiotic Parabacteroides goldsteinii in both male mice and pseudo‐germ mice receiving fecal sample from male mice. Sex‐biased gut metabolites in pseudo‐germ mice receiving fecal sample from CRC patients or CRC mice contribute to sex dimorphism in CRC tumorigenesis through glycerophospholipids metabolism pathway. Sexual dimorphism in tumorigenesis of CRC mouse models. In conclusion, the sex‐biased gut microbiome and metabolites contribute to sexual dimorphism in CRC. Modulating sex‐biased gut microbiota and metabolites could be a potential sex‐targeting therapeutic strategy of CRC.